Advertisement
Regular Articles

Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts

Jose Baselga, Larry Norton, Joan Albanell, Young-Mee Kim and John Mendelsohn
DOI:  Published July 1998

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2001 to March 2021

AbstractFull-text HTMLPDF
Total2218217820645

Cited By

Article Information

Volume 58, Issue 13, pp. 2825-2831

PubMed 
9661897
Published By 
American Association for Cancer Research
Print ISSN 
0008-5472
Online ISSN 
1538-7445
History 
  • Received February 9, 1998
  • Accepted May 1, 1998
  • Published first July 1, 1998.
Copyright & Usage 
©1998 American Association for Cancer Research.

Author Information

  1. Jose Baselga2,
  2. Larry Norton,
  3. Joan Albanell,
  4. Young-Mee Kim, and
  5. John Mendelsohn3
  1. Laboratory of Receptor Biology and Department of Medicine [J. B., Y-M. K., J. M.] and Breast Cancer Medicine Service [J. B., L. N.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; and Medical Oncology Service, Vall d'Hebron University Hospital, 08035 Barcelona, Spain [J. B., J. A.]

  • ↵3 Present address: U. T. M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.

Back to top

Open full page PDF
Article Alerts
Email Article
Citation Tools
Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts
Jose Baselga, Larry Norton, Joan Albanell, Young-Mee Kim and John Mendelsohn
Cancer Res July 1 1998 (58) (13) 2825-2831;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement